At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02171 CARSGEN-B
Closed 12-19 16:08:06
15.000
+0.190
+1.28%
High15.350Low14.780Vol896.00K
Open15.000D1 Closing14.810Amplitude3.85%
Mkt Cap8.57BTradable Cap8.57BTotal Shares571.00M
T/O13.52MT/O Rate0.16%Tradable Shares571.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CARsgen Therapeutics Extends Share Repurchase Program
MT Newswires Live  ·  11:36
CARsgen Therapeutics Extends Share Repurchase Program
BRIEF-Carsgen Therapeutics Says Yijie Concert Group Purchased 335,000 Shares From November 6 To December 17
Reuters  ·  12-18 23:03
BRIEF-Carsgen Therapeutics Says Yijie Concert Group Purchased 335,000 Shares From November 6 To December 17
CARsgen Therapeutics - Yijie Concert Group Purchased 335,000 Shares From November 6 to December 17
THOMSON REUTERS  ·  12-18 21:42
CARsgen Therapeutics - Yijie Concert Group Purchased 335,000 Shares From November 6 to December 17
Non-Executive Director Guo Huaqing Increases Stake in CARSGEN-B (02171) by 30,000 Shares at HK$14.98 per Share
Stock News  ·  12-18 15:44
Non-Executive Director Guo Huaqing Increases Stake in CARSGEN-B (02171) by 30,000 Shares at HK$14.98 per Share
HK Stock Buyback Summary | December 18
Stock News  ·  12-18 09:12
HK Stock Buyback Summary | December 18
CARSGEN-B Spent HK$6.737 Million to Repurchase 466,000 Shares on December 17
Deep News  ·  12-18 08:41
CARSGEN-B Spent HK$6.737 Million to Repurchase 466,000 Shares on December 17
HKEX Share Buyback Summary | December 17
Stock News  ·  12-17 09:12
HKEX Share Buyback Summary | December 17
CARsgen Therapeutics Holdings Insider Ups Holding During Year
Simply Wall St.  ·  12-17 07:17
CARsgen Therapeutics Holdings Insider Ups Holding During Year
CARSGEN-B (02171) Repurchases 1.01 Million Shares for HK$14.762 Million on December 16
Stock News  ·  12-16 21:54
CARSGEN-B (02171) Repurchases 1.01 Million Shares for HK$14.762 Million on December 16
CARSGEN-B (02171) Repurchases 522,000 Shares for HK$7.9076 Million on December 15
Stock News  ·  12-15
CARSGEN-B (02171) Repurchases 522,000 Shares for HK$7.9076 Million on December 15
CARsgen Therapeutics Repurchases 522,000 Shares for HKD 7.91 Million, Files Disclosure with HKEX
Reuters  ·  12-15
CARsgen Therapeutics Repurchases 522,000 Shares for HKD 7.91 Million, Files Disclosure with HKEX
CARSGEN-B (02171) Repurchases 250,000 Shares for HK$3.8945 Million on December 12
Stock News  ·  12-12
CARSGEN-B (02171) Repurchases 250,000 Shares for HK$3.8945 Million on December 12
CARsgen Therapeutics Repurchases 250,000 Shares for HKD 3.89 Million, Files Disclosure with HKEX
Reuters  ·  12-12
CARsgen Therapeutics Repurchases 250,000 Shares for HKD 3.89 Million, Files Disclosure with HKEX
Hong Kong Stock Buyback Summary | December 12
Stock News  ·  12-12
Hong Kong Stock Buyback Summary | December 12
CARSGEN-B (02171) Repurchased 1.02 Million Shares for Approximately HK$15.89 Million on December 11, 2025
Stock News  ·  12-11
CARSGEN-B (02171) Repurchased 1.02 Million Shares for Approximately HK$15.89 Million on December 11, 2025
Non-Executive Director Guo Huaqing Reduces Holdings in CARSGEN-B (02171) by 10,000 Shares at HK$17.7 Each
Stock News  ·  12-11
Non-Executive Director Guo Huaqing Reduces Holdings in CARSGEN-B (02171) by 10,000 Shares at HK$17.7 Each
CARsgen Announces Data of Allogeneic Bcma CAR-T Cell Therapy Ct0596 for Relapsed/Refractory Multiple Myeloma at the 2025 Ash Annual Meeting
THOMSON REUTERS  ·  12-08
CARsgen Announces Data of Allogeneic Bcma CAR-T Cell Therapy Ct0596 for Relapsed/Refractory Multiple Myeloma at the 2025 Ash Annual Meeting
CARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting
Stock News  ·  12-08
CARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting
CARsgen Therapeutics Presents Preliminary Results for Allogeneic CAR T-Cell Therapy CT0596 at ASH 2025
Reuters  ·  12-08
CARsgen Therapeutics Presents Preliminary Results for Allogeneic CAR T-Cell Therapy CT0596 at ASH 2025
CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma
Reuters  ·  12-07
CARsgen's Zevor-Cel Approved in China for Relapsed/Refractory Multiple Myeloma
No data available

Introduction

Company Name.
CARSGEN-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
Issue price:
--